Figure 5

Canthin-6-one synergises with VEGFR inhibitor sunitinib malate. (A–E’) Lateral fluorescent (A–E) and trans-light images (A–E’) of 48 hpf Tg(fli1a:EGFP) embryos treated with either 1% DMSO (A,A’), 20 µM sunitinib malate (SM, B,B’), 5 µM SM (C,C’), 10 µM canthin-6-one (D,D’), or co-treatment of 5 µM SM and 10 µM canthin-6-one (E,E’). White asterisks indicate the absence of intersegmental vessels (ISVs). (F,G) Quantification of the percentage of fully formed ISVs (F) or length of ISVs (G) in 48 hpf Tg(fli1a:EGFP) embryos treated with either 1% DMSO (n = 23), 20 µM SM (n = 22), 5 µM SM (n = 23), 10 µM canthin-6-one (n = 17), or co-treatment of 5 µM SM and 10 µM canthin-6-one (n = 21). Statistical test: Kruskal-Wallis test was conducted for graphs (F,G). p ≤ 0.0001 (****), p ≤ 0.001 (***), p ≤ 0.01 (**), p ≤ 0.05 (*), p > 0.05 (not significant, n.s.). Scale bar: 1 mm (A).